Orthofix Medical, Inc. (OFIX)

Orthofix Medical, Inc. has experienced several stock events in the past six months. The company reported a net loss of $(0.57) per share for Q3 2025, missing forecasts, but Q2 2025 earnings surpassed expectations with an EPS of $(0.36). The discontinuation of M6 product lines has impacted financial guidance. CEO Massimo Calafiore sold 9,600 shares of the company's stock in January 2026. As of January 2, 2026, the share price was $14.84, a decline of 14.47% from the previous year. Orthofix has received a consensus rating of "Moderate Buy" from analysts.

While specific seasonality data is unavailable, the demand for Orthofix Medical's products is driven by factors such as the rising incidence of orthopedic conditions, an increasing number of spinal fusion surgeries, and a growing geriatric population. The demand for bone growth stimulators is also boosted by increasing healthcare spending and a preference for non-invasive treatment options, suggesting a generally steady and growing demand.

Orthofix Medical, Inc. is a global medical technology company focused on reconstructive and regenerative musculoskeletal solutions. The company operates through its Global Spine and Global Orthopedics segments, offering products such as spinal hardware, bone growth therapies using pulsed electromagnetic fields (PEMF), specialized orthopedic solutions for trauma and limb reconstruction, biologics, enabling technologies like the 7D FLASH™ Navigation System, and motion preservation devices, although the M6 artificial disc product lines have been discontinued.

Orthofix has a global presence with its headquarters in Lewisville, Texas, and primary offices in Carlsbad, California, and Verona, Italy. The company's global footprint includes facilities and offices in Irvine, California; Toronto, Canada; Sunnyvale, California; Maidenhead, UK; Munich, Germany; Paris, France; and São Paulo, Brazil. Orthofix distributes its products in 68 countries worldwide.

Orthofix Medical's reputation was impacted by the firing of its CEO, CFO, and Chief Legal Officer in 2023 for inappropriate conduct. Subsequent litigation revealed offensive private texts shared between the trio, causing the stock to plummet 30% upon the initial announcement.

Orthofix Medical, Inc. is predominantly owned by institutional shareholders, who hold between 88.91% and 91.65% of the company's stock. Major institutional owners include Engine Capital Management LP, Rubric Capital Management LP, Paradigm Capital Management Inc/Ny, BlackRock, Inc., Juniper Investment Company, LLC, and Vanguard Group Inc. Insider ownership is relatively small, at 1.30% of the stock. Engine Capital Management LP is the largest individual shareholder, owning 10.74% of the company.